The US FDA has approved a pancreatic enzyme product (PEP) Pancreaze delayed release capsules manufactured by Johnson & Johnson.

PEPs improve food digestion in patients whose bodies do not produce enough pancreatic enzymes and those suffering from chronic pancreatitis, cystic fibrosis and pancreatic tumours.

The FDA has so far approved Creon manufactured by Abbott Products and Zenpep manufactured by Eurand Pharmaceuticals.

Pancreaze is the third PEP to receive FDA approval.

There is an estimated 200,000 patients or more in the US who need PEPs.